Search clinical trials for: Remibrutinib

Total 16 results

Novartis Pharmaceuticals

Active, not recruiting

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria

Spain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (BISCUIT)

Chronic Spontaneous Urticaria

Japan
Novartis Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)

Sjögren Syndrome

Spain, United States, Belgium, Hungary, Germany, Switzerland, Australia, Denmark, China, Taiwan, United Kingdom, Bulgaria
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines (REMIX-2)

Chronic Spontaneous Urticaria

United States, India, Malaysia, Taiwan, Poland, United Kingdom, China, Thailand, Switzerland, Germany, Vietnam, Brazil, Russian Federation, Slovakia, Denmark, Canada, South Africa, Austria
Novartis Pharmaceuticals

Recruiting

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Allergy, Peanut

United States, Spain
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, Chile, Canada
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

Hungary, Taiwan, Spain, Italy, Korea, Republic of, United States, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, Italy, China, Hungary, Czechia, Turkey, Argentina, Colombia, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Chronic Inducible Urticaria

China, United States, Australia, Korea, Republic of, Israel, Turkey, Hong Kong, Japan, Malaysia, Singapore, Thailand, Canada
Novartis Pharmaceuticals

Available

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, Czechia, India, Italy, Thailand, Turkey, Malaysia, Canada, Argentina, Bulgaria, Slovakia, Brazil, Poland
Mansoura University

Completed

Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

Urinary Incontinence | Urinary Bladder Cancer | Incontinence

Egypt
Karuna Therapeutics

Recruiting

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)

Schizophrenia

United States, Bulgaria, Serbia
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Relapsing Multiple Sclerosis

United States, Canada, China, Spain, Italy, France, Slovenia, Japan, Turkey, Argentina, Estonia, Greece, Mexico, Poland, Sweden, Croatia, South Africa, Brazil, Slovakia, Bulgaria, Romania, India, Portugal, United Kingdom, Puerto Rico
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, China, Spain, Switzerland, Italy, Belgium, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Lebanon, Guatemala, Netherlands, Colombia, Chile, United Kingdom, Denmark, Hong Kong, Ireland

Search clinical trials for: Remibrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations